Additional Resources

The websites shown below are neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of these sites.

World Federation of Hemophilia (WFH)

A not-for-profit organization dedicated to improving the lives of those with hemophilia and bleeding disorders worldwide.

Visit www.wfh.org

** This is an optional area where footnotes can live.

The National Hemophilia Foundation (NHF)

NHF is dedicated to finding better treatments and cures for bleeding disorders and to preventing the complications of these disorders through education, advocacy, and research.

Visit www.hemophilia.org

** This is an optional area where footnotes can live.

The International Society on Thrombosis and Haemostasis (ISTH)

ISTH is a global not-for-profit organization advancing the understanding, prevention, diagnosis, and treatment of thrombotic and bleeding disorders.

Visit www.isth.org

** This is an optional area where footnotes can live.

Hemostasis & Thrombosis Research Society (HTRS)

HTRS is a North American professional medical society dedicated to advancing care for people with bleeding and thrombotic disorders through investigator-initiated research, mentoring, and continuing medical education.

Visit www.htrs.org

** This is an optional area where footnotes can live.

North American Camping Conference for Hemophilia Organizations (NACCHO)

The only global conference dedicated to sharing best practices for summer camps for children in the bleeding disorders community. The Arizona Hemophilia Association conducts NACCHO yearly.

Visit www.arizonahemophilia.org/naccho

** This is an optional area where footnotes can live.

Support Your Patient

  • Resources for Patients and Caregivers
  • Additional Resources
View Support & Services
  • Do not use in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including hamster proteins.
  • Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with XYNTHA. Inform patients of the early signs or symptoms of hypersensitivity reactions (including hives, generalized urticaria, chest tightness, wheezing, and hypotension) and anaphylaxis. Discontinue XYNTHA if hypersensitivity symptoms occur and administer appropriate emergency treatment. XYNTHA contains trace amounts of hamster proteins. Patients may develop hypersensitivity to these proteins.
  • Inhibitors have been reported following administration of XYNTHA. Monitor patients for the development of factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • Clinical response to XYNTHA may vary. If bleeding is not controlled with the recommended dose of factor, determine the plasma level and administer a dose of XYNTHA sufficient to achieve clinical response. If the factor level does not increase or there is no response, suspect an inhibitor and perform appropriate testing.
  • Across all studies, the most common adverse reactions (≥10%) with XYNTHA in previously treated adult and pediatric patients were headache (24% of subjects), arthralgia (23%), fever (23%), and cough (12%). Other adverse reactions reported in ≥5% of subjects were diarrhea, vomiting, and weakness.
  • XYNTHA is an injectable medicine administered by intravenous (IV) infusion. Patients should be advised that local irritation may occur when infusing XYNTHA after reconstitution in XYNTHA® SOLOFUSE®.

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

XYNTHA is not indicated in patients with von Willebrand’s disease. 

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.

Indication

XYNTHA® Antihemophilic Factor (Recombinant) is indicated in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, for perioperative management, and for routine prophylaxis to reduce the frequency of bleeding episodes. 

XYNTHA is not indicated in patients with von Willebrand’s disease. 

Please see full Prescribing Information for XYNTHA and XYNTHA SOLOFUSE.